Diffuse choroidal haemangioma in Sturge–Weber syndrome treated with photodynamic therapy under general anaesthesia

Huiskamp, E. A.; Müskens, Rogier P.H.M.; Ballast, A.; Hooymans, Johanna M. M.

doi:10.1007/s00417-004-1102-9

Cited by 21 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most frequent treatment modality for diffuse choroidal hemangioma is external beam radiotherapy, with photons in 31 cases 73,74,81,113,138,148,162 and with protons in 21 cases. 47,81,221 The third most common method reported in the literature is PDT, which was used in 10 cases, where 7 cases were followed up after at least 6 months, 11,39,88,126,179,203 and 3 cases in 3 studies were followed up in less than 6 months. 9,18,203 In all cases treated with PDT, standard protocol with verteporfin was used, and the results are promising.Visual acuity increased, exudation resolved, and tumor size regressed.…”

Section: Diffuse Choroidal Hemangiomamentioning

confidence: 99%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

Section: Diffuse Choroidal Hemangiomamentioning

confidence: 99%

Clinical use of photodynamic therapy in ocular tumors

Çerman

Çekıç

2015

Survey of Ophthalmology

View full text Add to dashboard Cite

“…Huiskamp et al [13] reported PDT according to the standard protocol under general anesthesia for exudative retinal detachment associated with diffuse choroidal hemangioma in a 12-year-old girl with Sturge-Weber syndrome. Subretinal fluid resolved completely over a period of 5 months and VA increased from 20/400 to 20/50.…”

Section: Photodynamic Therapy Of Ocular Tumorsmentioning

confidence: 99%

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

et al. 2007

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597–599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these ‘case series’ and ‘individual case control studies’ have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).

show abstract

“…The tumoricidal activity of PDT is caused by direct cell damage and microvascular injury 2–4. PDT has been used for the management of various intraocular tumors including circumscribed5–8 and diffuse choroidal hemangioma,5–9 choroidal melanoma,10–12 retinal hemangioblastoma,13–16 retinal vasoproliferative tumor,1718 and retinal astrocytoma 19–21. We describe the development of transient tumor vascular hyperpermeability with increased intraretinal/subretinal fluid following PDT of three different types of intraocular tumors (retinal hemangioblastoma, retinal astrocytoma, amelanotic choroidal melanoma).…”

Section: Introductionmentioning

confidence: 99%

Transient increased exudation after photodynamic therapy of intraocular tumors

Mashayekhi

Shields

2013

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

To report transient increased exudation after photodynamic therapy (PDT) of three different intraocular tumors (retinal hemangioblastoma, retinal astrocytoma, amelanotic choroidal melanoma). PDT with verteporfin (6 mg/m2 body surface area) was delivered at a dose of 50 J/cm2 and intensity of 600 mW/cm2 over 83 s. All patients experienced decreased vision within a few days following PDT. Optical coherence tomography showed development of subfoveal fluid in all cases and noncystoid intraretinal edema in the eye with juxtapapillary retinal hemangioblastoma. There was complete absorption of retinal/subretinal fluid with improvement of visual acuity to 20/20 in all cases between 3 weeks to 4 months after PDT.

show abstract

Diffuse choroidal haemangioma in Sturge–Weber syndrome treated with photodynamic therapy under general anaesthesia

Cited by 21 publications

References 11 publications

Clinical use of photodynamic therapy in ocular tumors

Clinical use of photodynamic therapy in ocular tumors

Ocular Photodynamic Therapy – Standard Applications and New Indications (Part 2)

Transient increased exudation after photodynamic therapy of intraocular tumors

Contact Info

Product

Resources

About